Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis
- 21 April 2004
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 57 (6), 735-741
- https://doi.org/10.1111/j.1365-2125.2004.02077.x
Abstract
To develop a population pharmacokinetic model for pyrimethamine (PYR) and sulfadoxine (SDX) in children with congenital toxoplasmosis. Children were treated with PYR (1.25 mg kg(-1)) and SDX (25 mg kg(-1)) (Fansidar) plus folinic acid (Lederfoline) 5 mg). Plasma concentrations, available from a therapeutic drug monitoring database, were determined by high-performance liquid chromatography. Population pharmacokinetic analysis was performed using a nonlinear mixed effects model. Eighty-nine children, aged 1 week to 14 years and weighing 2.9-59 kg, were available for evaluation. Both PYR and SDX concentration-time profiles were best described by a one-compartment open model. Volume of plasma distribution (V) and clearance (CL) were significantly related to body weight (BW) using an allometric function. Typical CL and V estimates (95% confidence interval), for a child weighing 11 kg were 5.50 (5.28, 5.73) l day(-1) and 36 (33, 39) l for PYR and 0.26 (0.25, 0.27) l day(-1) and 2.1 (1.9, 2.3) l for SDX. For BW between 3.5 and 60 kg, plasma half-lives were predicted to vary from 4.0 to 5.2 days for PYR, and from 5.0 to 7.5 days for SDX. This study indicated that body weight influences PYR and SDX pharmacokinetics in children. To optimize PYR/SDX combination treatment in congenital toxoplasmosis, short dosing intervals in very young low-wight children are probably appropriate.Keywords
This publication has 21 references indexed in Scilit:
- COMMENTARY ON BROWN ET AL.'S “TOWARD A METABOLIC THEORY OF ECOLOGY”Ecology, 2004
- A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and childrenBritish Journal of Clinical Pharmacology, 2000
- Pyrimethamine-sulfadoxine Treatment of Congenital Toxoplasmosis: Follow-up of 78 Cases Between 1980 and 1997Scandinavian Journal of Infectious Diseases, 1998
- In vitro effects of sulfadiazine and its metabolites alone and in combination with pyrimethamine on Toxoplasma gondiiAntimicrobial Agents and Chemotherapy, 1995
- Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study GroupAntimicrobial Agents and Chemotherapy, 1992
- Fetal toxoplasmosis: Outcome of pregnancy and infant follow-up after in utero treatmentThe Journal of Pediatrics, 1989
- Enzyme immunoassay to assess effect of antimicrobial agents on Toxoplasma gondii in tissue cultureAntimicrobial Agents and Chemotherapy, 1988
- Prenatal Management of 746 Pregnancies at Risk for Congenital ToxoplasmosisNew England Journal of Medicine, 1988
- In Vitro Assessment of Antimicrobial Agents Against Toxoplasma gondiiThe Journal of Infectious Diseases, 1988
- RESULTS OF 20-YEAR FOLLOW-UP OF CONGENITAL TOXOPLASMOSISThe Lancet, 1986